TCG Advisory Services LLC Sells 81 Shares of Zoetis Inc. (NYSE:ZTS)

TCG Advisory Services LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 5.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,339 shares of the company’s stock after selling 81 shares during the quarter. TCG Advisory Services LLC’s holdings in Zoetis were worth $264,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky raised its stake in shares of Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in Zoetis during the third quarter valued at approximately $35,000. First Financial Corp IN grew its holdings in Zoetis by 57.2% in the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after purchasing an additional 79 shares during the period. Finally, Bogart Wealth LLC increased its position in shares of Zoetis by 188.9% during the third quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock worth $45,000 after purchasing an additional 170 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 2,209 shares of company stock worth $371,293 over the last quarter. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

ZTS has been the topic of several research reports. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays reduced their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group lifted their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average price target of $216.13.

Zoetis Stock Down 0.5 %

Shares of NYSE ZTS traded down $0.88 during mid-day trading on Monday, reaching $166.19. The company had a trading volume of 557,151 shares, compared to its average volume of 3,147,119. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock has a market capitalization of $75.83 billion, a PE ratio of 32.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The stock’s 50 day moving average is $168.88 and its 200-day moving average is $178.93.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same period in the prior year, the company earned $1.31 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is 33.33%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.